WO2012174224A3 - Procédés d'administration de produits thérapeutiques à base d'acide nucléique - Google Patents

Procédés d'administration de produits thérapeutiques à base d'acide nucléique Download PDF

Info

Publication number
WO2012174224A3
WO2012174224A3 PCT/US2012/042433 US2012042433W WO2012174224A3 WO 2012174224 A3 WO2012174224 A3 WO 2012174224A3 US 2012042433 W US2012042433 W US 2012042433W WO 2012174224 A3 WO2012174224 A3 WO 2012174224A3
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acid
methods
dose amount
based therapeutic
administering
Prior art date
Application number
PCT/US2012/042433
Other languages
English (en)
Other versions
WO2012174224A2 (fr
Inventor
Thomas Schluep
Original Assignee
Calando Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Calando Pharmaceuticals, Inc. filed Critical Calando Pharmaceuticals, Inc.
Publication of WO2012174224A2 publication Critical patent/WO2012174224A2/fr
Publication of WO2012174224A3 publication Critical patent/WO2012174224A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/35—Special therapeutic applications based on a specific dosage / administration regimen

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des procédés d'administration d'un produit thérapeutique à base d'acide nucléique pour traiter une maladie ou un trouble chez un patient. Les procédés comprennent de façon appropriée l'administration d'une première quantité posologique d'un produit thérapeutique à base d'acide nucléique au cours d'un premier cycle de traitement et l'administration d'une seconde quantité posologique du produit thérapeutique à base d'acide nucléique au cours de cycles de traitement ultérieurs, la première quantité posologique étant inférieure à la seconde quantité posologique. Dans divers modes de réalisation, le produit thérapeutique à base d'acide nucléique est un siARN qui fait partie d'une composition comprenant un polymère cyclodextrine.
PCT/US2012/042433 2011-06-17 2012-06-14 Procédés d'administration de produits thérapeutiques à base d'acide nucléique WO2012174224A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161498293P 2011-06-17 2011-06-17
US61/498,293 2011-06-17

Publications (2)

Publication Number Publication Date
WO2012174224A2 WO2012174224A2 (fr) 2012-12-20
WO2012174224A3 true WO2012174224A3 (fr) 2013-02-21

Family

ID=47357728

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/042433 WO2012174224A2 (fr) 2011-06-17 2012-06-14 Procédés d'administration de produits thérapeutiques à base d'acide nucléique

Country Status (1)

Country Link
WO (1) WO2012174224A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2902393C (fr) * 2013-02-28 2022-11-01 Arrowhead Research Corporation Compositions organiques destinees a traiter les maladies liees au gene epas1
US20160030527A1 (en) * 2013-03-14 2016-02-04 The Trustees Of The University Of Pennsylvania Compositions and Methods for Treatment of Stroke
US20160032316A1 (en) 2013-03-14 2016-02-04 The Trustees Of The University Of Pennsylvania Purification and Purity Assessment of RNA Molecules Synthesized with Modified Nucleosides
EP4249036A3 (fr) * 2014-01-31 2023-10-25 Factor Bioscience Inc. Procédés et produits pour la production et l'administration d'acide nucléique
EP3543339A1 (fr) 2015-02-13 2019-09-25 Factor Bioscience Inc. Produits d'acides nucléiques et leurs procédés d'administration
MX2017014641A (es) 2015-05-29 2018-01-23 Arrowhead Pharmaceuticals Inc Composiciones y metodos para inhibir la expresion del gen de factor inducible por hipoxia alfa (hif2alfa).
IL264439B1 (en) 2016-08-17 2024-04-01 Factor Bioscience Inc A suitable viral preparation containing a synthetic messenger RNA encoding a gene editing protein for use in cancer treatment and a synthetic messenger RNA encoding a gene editing protein for use in therapy
US10501404B1 (en) 2019-07-30 2019-12-10 Factor Bioscience Inc. Cationic lipids and transfection methods
FR3112684B1 (fr) * 2020-07-24 2022-08-12 Univ Grenoble Alpes Composés pour le traitement de l’hémophilie

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7427605B2 (en) * 2005-03-31 2008-09-23 Calando Pharmaceuticals, Inc. Inhibitors of ribonucleotide reductase subunit 2 and uses thereof
US20100010071A1 (en) * 2008-04-04 2010-01-14 Calando Pharmaceuticals, Inc. Compositions and use of EPAS1 inhibitors
US20100010066A1 (en) * 2008-01-31 2010-01-14 Kevin Fitzgerald Optimized Methods For Delivery Of DSRNA Targeting The PCSK9 Gene

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7427605B2 (en) * 2005-03-31 2008-09-23 Calando Pharmaceuticals, Inc. Inhibitors of ribonucleotide reductase subunit 2 and uses thereof
US20100010066A1 (en) * 2008-01-31 2010-01-14 Kevin Fitzgerald Optimized Methods For Delivery Of DSRNA Targeting The PCSK9 Gene
US20100010071A1 (en) * 2008-04-04 2010-01-14 Calando Pharmaceuticals, Inc. Compositions and use of EPAS1 inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PINKEL: "The use of body surface area as a criterion of drug dosage in cancer chemotherapy", CANCER RES., vol. 18, no. 7, August 1958 (1958-08-01), pages 853 - 6 *

Also Published As

Publication number Publication date
WO2012174224A2 (fr) 2012-12-20

Similar Documents

Publication Publication Date Title
WO2012174224A3 (fr) Procédés d'administration de produits thérapeutiques à base d'acide nucléique
NZ719520A (en) Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway
EA201490004A1 (ru) Применение bifidobacterium lactis bl-04 для лечения заболеваний дыхательных путей
JP2012046524A5 (fr)
NZ716473A (en) Diagnosis and therapy of cancer involving cancer stem cells
WO2013169864A3 (fr) Tétrahydro[1,8]naphtyridine-sulfonamide et composés apparentés pour utilisation en tant qu'agonistes de rorγ et dans le traitement d'une maladie
MX362626B (es) Métodos para tratar pacientes pediátricos usando dexmedetomidina..
WO2014022739A3 (fr) Agents constitués d'arni modifié
NZ626954A (en) Combination therapy of antibodies against human csf-1r and uses thereof
WO2012062925A3 (fr) Composés et procédés de traitement de la douleur
BR112014014262A2 (pt) nanopartículas; composição farmacêutica; método de administrar um ou mais agentes terapêuticos, profiláticos, e/ou diagnósticos a um paciente em necessidade dos mesmos e método de preparação das partículas.
MX2011007589A (es) Tratamiento de un cancer usando una combinacion de bendamustine y un anticuerpo anti-cd20.
AR082312A1 (es) Una composicion farmaceutica de combinacion para tratar diabetes y desordenes metabolicos
IN2015DN00450A (fr)
NZ702730A (en) Treatment of motor and movement disorder side effects associated with parkinson’s disease treatments
WO2014080286A3 (fr) Méthodes et compositions pour le traitement de la sclérose en plaques et de troubles associés
MX2014006762A (es) Metodos para el tratamiento de desordenes cardiovasculares.
MX2016000220A (es) Regulacion del metabolismo de glucosa usando anticuerpos anti-cgrp.
MX2014000777A (es) Cateter, en particular cateter permanente para el tratamiento de disfunciones y/o enfermedades de la vejiga y/o la prostata.
EP3517115A3 (fr) Méthodes d'utilisation de la mésoporphyrine d'étain pour le traitement de l'hyperbilirubinémie
GB201022049D0 (en) Methods
WO2012016229A3 (fr) Traitement à l'ocytocine visant à améliorer la mémoire et abaisser le taux de glucose dans le sang
WO2012006585A3 (fr) Utilisation de l'interleukine-15 dans le traitement de maladies cardiovasculaires
MX2015008171A (es) Formulacion que comprende agomelatina amorfa.
MX2014013380A (es) Usos de cxcl17, un nuevo marcador de quimiocinas de enfermedad pulmonar y gastrointestinal humana.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12800412

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12800412

Country of ref document: EP

Kind code of ref document: A2